Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB

Nat Commun. 2022 Nov 21;13(1):7131. doi: 10.1038/s41467-022-34892-4.

Abstract

The nuclear receptor REV-ERB plays an important role in a range of physiological processes. REV-ERB behaves as a ligand-dependent transcriptional repressor and heme has been identified as a physiological agonist. Our current understanding of how ligands bind to and regulate transcriptional repression by REV-ERB is based on the structure of heme bound to REV-ERB. However, porphyrin (heme) analogues have been avoided as a source of synthetic agonists due to the wide range of heme binding proteins and potential pleotropic effects. How non-porphyrin synthetic agonists bind to and regulate REV-ERB has not yet been defined. Here, we characterize a high affinity synthetic REV-ERB agonist, STL1267, and describe its mechanism of binding to REV-ERB as well as the method by which it recruits transcriptional corepressor both of which are unique and distinct from that of heme-bound REV-ERB.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Heme / metabolism
  • Ligands
  • Nuclear Receptor Subfamily 1, Group D, Member 1* / genetics
  • Porphyrins* / pharmacology

Substances

  • Nuclear Receptor Subfamily 1, Group D, Member 1
  • Heme
  • Ligands
  • Porphyrins